Human monocytotropic ehrlichiosis

Signs and symptoms

The most common symptoms are fever, headache, malaise, and muscle aches (myalgia). Compared to human granulocytic anaplasmosis, rash is more common. Laboratory abnormalities include thrombocytopenia, leukopenia, and elevated liver tests.

The severity of the illness can range from minor or asymptomatic to life-threatening. CNS involvement may occur. A serious septic or toxic shock-like picture can also develop, especially in patients with impaired immunity.

Cause

This disease is known to be caused by tick bites.

Diagnosis

Tick exposure is often overlooked. For patients living in high-prevalence areas who spend time outdoors, a high degree of clinical suspicion should be employed. Ehrlichia serologies can be negative in the acute period. Polymerase chain reaction is therefore the laboratory diagnostic tool of choice.

Treatment

If ehrlichiosis is suspected, treatment should not be delayed while waiting for a definitive laboratory confirmation, as prompt doxycycline therapy has been associated with improved outcomes. Doxycycline is the treatment of choice.

Presentation during early pregnancy can complicate treatment. Rifampin has been used in pregnancy and in patients allergic to doxycycline.

Epidemiology

In the US, human monocytotropic ehrlichiosis occurs across the south-central, southeastern, and mid-Atlantic states, regions where both the white-tailed deer (Odocoileus virginianus) and its ectoparasite, Lone Star ticks (Amblyomma americanum), thrive.

Human monocytotropic ehrlichiosis occurs in California in Ixodes pacificus ticks and in Dermacentor variabilis ticks. Nearly 600 cases were reported to the CDC in 2006. In 2001–2002, the incidence was highest in Missouri, Tennessee, and Oklahoma, as well as in people older than 60.

References

References

1. (2007). "Dermatology". Mosby.
2. (June 2007). "Human monocytic ehrlichiosis in children". Pediatr. Infect. Dis. J..
3. (March 2007). "The developmental cycle of Ehrlichia chaffeensis in vertebrate cells". Cellular Microbiology.
4. (December 2005). "Human granulocytic anaplasmosis and ''Anaplasma phagocytophilum''". Emerging Infectious Diseases.
5. (November 2001). "Infections with ''Ehrlichia chaffeensis'' and ''Ehrlichia ewingii'' in persons coinfected with human immunodeficiency virus". Clinical Infectious Diseases.
6. (17 January 2019). "Ehrlichiosis – Transmission".
7. (August 2007). "Ehrlichiosis: making the diagnosis in the acute setting". Southern Medical Journal.
8. (March 2008). "The importance of early treatment with doxycycline in human ehrlichiosis". Medicine.
9. (2008). "Human granulocytic ehrlichiosis complicating early pregnancy". Infect Dis Obstet Gynecol.
10. (September 2003). "Successful treatment of human granulocytic ehrlichiosis in children using rifampin". Pediatrics.
11. (2021). "Lone Star Ticks (''Amblyomma americanum''): An Emerging Health Threat in Delaware". Delaware Journal of Public Health.
12. (17 January 2019). "Ehrlichiosis: Transmission".
13. (15 December 2023). "Tickborne Diseases of the United States: Ehrlichiosis".
14. (July 2003). "Detection of ''Borrelia burgdorferi'', ''Ehrlichia chaffeensis'', and ''Anaplasma phagocytophilum'' in ticks (Acari: Ixodidae) from a coastal region of California". J. Med. Entomol..
15. (5 September 2013). "Statistics and Epidemiology: Annual Cases of Ehrlichiosis in the United States". Division of Vector-Borne Diseases (DVBD), National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Centers for Disease Control and Prevention.